A global research team co-led by the Institute for Bioengineering of Catalonia (IBEC) and West China Hospital, Sichuan University (WCHSU), in collaboration with UK partners, has demonstrated a groundbreaking nanotechnology approach that reverses Alzheimer’s disease in mice. Unlike conventional nanomedicines that serve as drug carriers, this new strategy uses bioactive nanoparticles, or “supramolecular drugs,” that actively restore brain function. The findings were published in Signal Transduction and Targeted Therapy.
Restoring the Blood–Brain Barrier to Reverse Disease
Instead of targeting neurons directly, the therapy focuses on repairing the blood–brain barrier (BBB) — the brain’s protective interface that regulates its internal environment. By restoring BBB function, researchers successfully reversed Alzheimer’s pathology in animal models. The BBB acts as a cellular and physiological shield, protecting the brain from toxins and pathogens. However, in Alzheimer’s, its dysfunction contributes to the buildup of toxic proteins.
Brain Vasculature: A Crucial Lifeline
The brain consumes nearly 20% of the body’s energy in adults and up to 60% in children, depending on its dense network of about one billion capillaries. This vast vascular system is essential for nourishing neurons and maintaining brain health. The study underscores how vascular dysfunction accelerates neurodegenerative conditions like dementia and Alzheimer’s, where a compromised blood supply is closely linked to disease progression.
Targeting Amyloid-β Clearance Mechanisms
One hallmark of Alzheimer’s is the accumulation of amyloid-β (Aβ), a toxic protein that disrupts neuron function. Under normal conditions, a protein called LRP1 clears Aβ from the brain by ferrying it across the BBB into the bloodstream. However, in Alzheimer’s, this system fails — either from excessive binding or insufficient signaling — leading to Aβ buildup.
The newly developed supramolecular drugs act like a reset switch, mimicking LRP1’s natural ligands. They bind to amyloid-β (Aβ) and cross the blood–brain barrier (BBB). Once across, they activate the brain’s clearance pathway. This process restores the vasculature’s natural waste-clearing role, helping the brain regain balance and function.
Rapid and Sustained Therapeutic Effects
As reported by medicalxpress, the team tested the therapy on genetically engineered mice prone to excessive Aβ production and cognitive decline. After administering only three doses of the supramolecular drugs, researchers observed a 50–60% reduction in brain Aβ levels within one hour. Behavioral studies confirmed sustained improvement in memory and cognitive function.
In one experiment, a 12-month-old mouse (comparable to a 60-year-old human) was treated and assessed six months later. Remarkably, by the equivalent of 90 human years, the mouse exhibited behavior typical of a healthy animal.
Dr. Giuseppe Battaglia, ICREA Research Professor at IBEC and leader of the study, explained, “The long-term effect arises from restoring the brain’s vasculature. Once the blood vessels regain their function, they start clearing amyloid-beta and other harmful molecules, allowing the entire system to recover.”
Engineering the Next Generation of Therapeutics
These nanoparticles were designed using bottom-up molecular engineering, allowing precise control over size and surface properties. Each nanoparticle carries a defined number of ligands, enabling highly specific interactions with cellular receptors. By influencing receptor trafficking, the supramolecular drugs open a novel therapeutic pathway for modulating brain function.
According to Lorena Ruiz Perez, researcher at IBEC’s Molecular Bionics Group and Serra Hunter Assistant Professor at the University of Barcelona, “Our study demonstrated remarkable efficacy in achieving rapid amyloid-beta clearance and restoring healthy blood–brain barrier function, leading to a striking reversal of Alzheimer’s pathology.”
Collaborative Global Effort
The breakthrough study involved contributions from IBEC, West China Hospital and Xiamen Hospital of Sichuan University, University College London, the University of Barcelona, the Xiamen Key Laboratory of Psychoradiology and Neuromodulation, the Chinese Academy of Medical Sciences, and ICREA.
A New Direction for Alzheimer’s Treatment
By shifting focus from neurons to vascular restoration, this nanotechnology-based approach opens a transformative path for Alzheimer’s therapy. It highlights how rebuilding the brain’s natural clearance mechanisms can halt — and even reverse — the disease’s progression. This approach offers renewed hope for millions affected worldwide.